Immunotherapy: an emerging modality to checkmate brain metastasis

Table 2 Key immunotherapy drugs used in various cancer types to treat brain metastases

Immunotherapy Drug	Drug Class	Primary Cancer Type	References
Pembrolizumab	Anti-PD-1	NSCLC, BC(ER+), Melanoma, RCC	[1, 40, 77, 78, 85, 93, 95, 96, 119, 120, 147]
Tislelizumab	Anti-PD-1	NSCLC	[92]
Atezolizumab	Anti-PD-L1	NSCLC	[79, 111, 127]
Sintilimab	Anti-PD-1	NSCLC, SCLC	[94, 124, 127]
Toripalimab	Anti-PD-1	SCLC	[124, 127]
Adrebrelimab	Anti-PD-L1	SCLC	[126]
Durvalumab	Anti-PD-L1	SCLC	[125, 127]
Camrelizumab	Anti-PD-1	SCLC	[127]
Nivolumab	Anti-PD-1	SCLC, Melanoma, NSCLC, RCC	[40, 50, 53,54,55, 102, 103, 127, 170, 172, 264]
Ipilimumab	Anti-CTLA-4	Melanoma, NSCLC, RCC	[38, 40, 44, 50, 53,54,55, 172]
Relatlimab (only in combination with nivolumab)	Anti-LAG3	Melanoma	[41, 56, 64]

ISSN: 1476-4598